JPS6225125B2 - - Google Patents
Info
- Publication number
- JPS6225125B2 JPS6225125B2 JP53073367A JP7336778A JPS6225125B2 JP S6225125 B2 JPS6225125 B2 JP S6225125B2 JP 53073367 A JP53073367 A JP 53073367A JP 7336778 A JP7336778 A JP 7336778A JP S6225125 B2 JPS6225125 B2 JP S6225125B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- vitamin
- serum
- diet
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011575 calcium Substances 0.000 claims description 70
- 229910052791 calcium Inorganic materials 0.000 claims description 69
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000010304 firing Methods 0.000 claims description 9
- 241000237502 Ostreidae Species 0.000 claims description 8
- 235000020636 oyster Nutrition 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960005069 calcium Drugs 0.000 description 68
- 235000005911 diet Nutrition 0.000 description 15
- 230000037213 diet Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 229930003316 Vitamin D Natural products 0.000 description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000019166 vitamin D Nutrition 0.000 description 10
- 239000011710 vitamin D Substances 0.000 description 10
- 150000003710 vitamin D derivatives Chemical class 0.000 description 10
- 229940046008 vitamin d Drugs 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 6
- 239000001527 calcium lactate Substances 0.000 description 6
- 229960002401 calcium lactate Drugs 0.000 description 6
- 235000011086 calcium lactate Nutrition 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002990 parathyroid gland Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229940034055 calcium aspartate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- -1 silicate ion Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Landscapes
- Meat, Egg Or Seafood Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Description
【発明の詳細な説明】
本発明は吸収性の著しく高められたカルシウム
剤に関するものである。さらに詳しくいうと、本
発明は、貝殻を酸素を遮断した状態において高温
で焼成することによつて得た粉末状焼成体からな
るカルシウム剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a calcium agent with significantly increased absorption. More specifically, the present invention relates to a calcium agent consisting of a powdered fired body obtained by firing seashells at high temperatures in a state where oxygen is blocked.
従来、カルシウム剤としては、乳酸カルシウ
ム、グルコン酸カルシウム、アスパラギン酸カル
シウムなどが用いられているが、これらのものは
腸管からの吸収が悪く、また消化管に対して刺激
を与えるなどの難点を持つ。また、カルシウム剤
としては、必要なカルシウム量を服用するのに便
利なように、単位容積あるいは単位重量当りのカ
ルシウム含量が高いものが望まれている。 Conventionally, calcium lactate, calcium gluconate, calcium aspartate, etc. have been used as calcium agents, but these have drawbacks such as poor absorption from the intestinal tract and irritation to the gastrointestinal tract. . Further, calcium preparations are desired to have a high calcium content per unit volume or unit weight so that it is convenient to take the required amount of calcium.
本発明によるカルシウム剤は、腸管からの吸収
性が著しく高められ、また単位重量当りのカルシ
ウム含量が高いという特徴を有する。 The calcium agent according to the present invention is characterized by significantly increased absorption from the intestinal tract and high calcium content per unit weight.
本発明においてカルシウム剤原料としては、か
きの貝殻が用いられ、たとえば、マガキ、ナガガ
キ、近江ガキ、僧帽ガキ、覆瓦ガキの貝殻が適用
される。これらのかきの貝殻は、これをそのまま
粉砕した粉末状で漢方薬として使用されているも
のである。 In the present invention, oyster shells are used as the calcium agent raw material, and for example, shells of Japanese oysters, Japanese oysters, Omi oysters, mitral oysters, and oyster oysters are applicable. These oyster shells are ground into powder and used as Chinese medicine.
本発明のカルシウム剤を得るには、このかき貝
殻を酸素を遮断した状態で高温に焼成して焼成体
としたのち、微粉末に粉砕する。また、このかき
貝殻は微粉砕したのち焼成してもよい。この場
合、焼成温度としては、1600〜2000℃の温度が採
用される。また、酸素遮断下の焼成手段として
は、電気炉は真空下（約10-3mmHg以下）で操作
することにより酸素の影響を回避することができ
るが、かきの貝殻の焼成に際しては炭酸ガスの発
生を伴なうので、電気炉に焼成ガス逸出用の排出
口を設けて焼成することにより、炉内の空気は逸
出され、酸素の影響は実質上回避される。焼成時
間は30〜90分、通常、40〜60分間程度である。 In order to obtain the calcium agent of the present invention, the oyster shell is fired at a high temperature in an oxygen-blocked state to form a fired body, which is then ground into a fine powder. Further, the oyster shell may be pulverized and then fired. In this case, the firing temperature is 1600 to 2000°C. In addition, as a means of firing with oxygen cutoff, electric furnaces can be operated under vacuum (approximately 10 -3 mmHg or less) to avoid the effects of oxygen, but when firing oyster shells, carbon dioxide gas is not used. Therefore, by providing an electric furnace with an outlet for escaping the firing gas and firing, the air inside the furnace can escape and the influence of oxygen can be substantially avoided. Firing time is 30 to 90 minutes, usually about 40 to 60 minutes.
このようにして得られた焼成体は、銀色又は白
茶色を帯びた白色の微粉末であり、１ｇ中のカル
シウム含量は約530mgという非常に高いものであ
る。また、このものは腸管からの吸収性が非常に
高く、カルシウム剤としては非常にすぐれたもの
である。本発明によるカルシウム剤は、微粉末
状、粒状あるいは水に溶解した液状で適用され
る。 The calcined product thus obtained is a silvery or whitish-brown white fine powder, and has a very high calcium content of about 530 mg per gram. Additionally, this product has very high absorbability from the intestinal tract, making it an excellent calcium agent. The calcium agent according to the present invention is applied in the form of fine powder, granules, or liquid dissolved in water.
次に本発明を実施例によりさらに詳細に説明す
る。 Next, the present invention will be explained in more detail with reference to Examples.
実施例
原料としてのマガキのかき貝殻１Kgをガス排出
口を有する電気炉において温度1800℃で50分間加
熱焼成したのち、粉砕し、微粉末状の焼成体約
450ｇを得た。Example: 1 kg of oyster shells as a raw material was heated and fired in an electric furnace with a gas outlet at a temperature of 1800°C for 50 minutes, and then crushed to produce a finely powdered fired body.
Obtained 450g.
この場合の貝殻焼成の結果は次の通りである。 The results of shell firing in this case are as follows.
強熱減量20.60％、CaO73.6％、MgO0.08％、
SiO20.65％、Al2O31.44％、Fe2O30.27％、
TiO20.1％以下、Na2O1.68％、K2O0.09％、
SO32.08％、P2O50.16％、Cl-0.08％、CO21.7
％。 Ignition loss 20.60%, CaO73.6%, MgO0.08%,
SiO2 0.65%, Al2O3 1.44 %, Fe2O3 0.27 %,
TiO 2 0.1% or less, Na 2 O 1.68%, K 2 O 0.09%,
SO3 2.08%, P2O5 0.16 %, Cl - 0.08%, CO2 1.7
%.
また、焼成体1.5ｇを水0.5に溶かした溶液の
特性は次の通りである。 Further, the characteristics of a solution prepared by dissolving 1.5 g of the fired body in 0.5 g of water are as follows.
PH12.5、アルカリ度45.4ミリ当量／、
Ca2+884mg／、Mg2+0.1mg／以下、Na+58mg／
、K+2.1mg／、Cl-48mg／、SO4 2-180mg／
、ケイ酸イオン（SiO2として）10mg／以
下、リン酸イオン（PO4）１mg／以下。 PH12.5, alkalinity 45.4 milliequivalent/,
Ca 2+ 884mg/, Mg 2+ 0.1mg/ or less, Na + 58mg/
, K + 2.1mg/, Cl - 48mg/, SO 4 2- 180mg/
, silicate ion (as SiO 2 ) 10 mg/or less, phosphate ion (PO 4 ) 1 mg/or less.
次に、この微粉末状カルシウム剤（カルシウム
剤Ａと略記）の腸管からの吸収の程度を知るため
に、動物実験として、ラツトを用い、その副甲状
腺を摘除して血清カルシウムを低下させ、活性型
のビタミンＤの合成の低下と腸管からのカルシウ
ムの吸収を低下させた後、カルシウム剤を経口的
に投与して血清カルシウムを上昇させる程度を比
較した。 Next, in order to determine the extent of absorption of this finely powdered calcium preparation (abbreviated as calcium preparation A) from the intestinal tract, we conducted an animal experiment using rats, removed their parathyroid glands, lowered serum calcium, and After reducing vitamin D synthesis and calcium absorption from the intestinal tract, calcium preparations were orally administered to compare the extent to which serum calcium was increased.
Wister系雄ラツト（体積200ｇ）20匹を用い、
エーテル麻酔下焼灼によつて副甲状腺を摘除し、
摘出前(1)及び24時間後(2)に血清カルシウムを
OCPC法で測定した。ラツトは５匹づつの４群に
分けて次の実験群に示すように異なつたカルシウ
ム剤を与え、副甲状腺摘除後６日目(3)に採血し、
血清カルシウムをOCPC法で測定した。
Using 20 Wister male rats (volume 200g),
The parathyroid glands were removed by cauterization under ether anesthesia,
Serum calcium was measured before (1) and 24 hours after (2) extraction.
Measured by OCPC method. Rats were divided into 4 groups of 5 rats each, given different calcium supplements as shown in the following experimental groups, and blood was collected on the 6th day after parathyroidectomy (3).
Serum calcium was measured by the OCPC method.
実験群
第１群（コントロール群）
副甲状腺摘除前３日間摘除後採血まで１日間、
採血後６日間すべて低カルシウム・ビタミンＤ欠
乏食（日本クレア株式会社製）を与えた。Experimental group 1st group (control group) 3 days before parathyroidectomy 1 day after removal of blood until blood sampling
A low-calcium, vitamin D-deficient diet (manufactured by CLEA Japan Co., Ltd.) was fed for 6 days after blood collection.
第２群（カルシウム剤Ａ群）
副甲状腺摘除前３日間摘除後採血まで１日間は
低カルシウム・ビタミンＤ欠乏食を投与し、採血
後６日間は同じ低カルシウム・ビタミンＤ欠乏食
に、本発明によるカルシウム剤Ａをカルシウム含
量が1.2％になるように加えて投与した。なお、
このカルシウム剤Ａは１ｇ中にカルシウム526mg
を含有した。 Group 2 (calcium agent group A) A low calcium and vitamin D deficient diet was administered for 3 days before parathyroidectomy and 1 day after blood collection, and the same low calcium and vitamin D deficient diet was administered for 6 days after blood collection, according to the present invention. Calcium agent A according to the author was added to the patient so that the calcium content was 1.2%. In addition,
This calcium agent A has 526mg of calcium in 1g.
Contained.
第３群（乳酸カルシウム群）
副甲状腺摘除前３日間、摘除後採血まで１日間
は低カルシウム・ビタミンＤ欠乏食を投与し、採
血後６日間は同じ低カルシウム・ビタミンＤ欠乏
食に乳酸カルシウム（１ｇ中にカルシウム130mg
を含む）をカルシウム含量が食餌中に1.2％にな
るように投与した。 Group 3 (calcium lactate group) A low-calcium, vitamin D-deficient diet was administered for 3 days before parathyroidectomy and 1 day after blood sampling, and for 6 days after blood sampling, calcium lactate (calcium lactate) was administered on the same low-calcium, vitamin D-deficient diet for 6 days after blood sampling. Calcium 130mg in 1g
) was administered so that the calcium content was 1.2% in the diet.
第４群（ワダカルシウム群）
副甲状腺摘除前３日間、摘除後採血まで１日間
は低カルシウム・ビタミンＤ欠乏食を投与し、採
血後６日間は同じ低カルシウム・ビタミンＤ欠乏
食にワダカルシウム（クエン酸カルシウム、乳酸
カルシウム、リン酸カルシウムの混合物）（１ｇ
中にカルシウム60mgを含む）をカルシウム含量が
食餌中に1.2％になるように加えた。 Group 4 (Wada Calcium Group) A low-calcium, vitamin D-deficient diet was administered for 3 days before parathyroidectomy and 1 day after blood collection, and for 6 days after blood collection, the same low-calcium, vitamin D-deficient diet was followed by Wada calcium (Wada Calcium). mixture of calcium citrate, calcium lactate, calcium phosphate) (1g
(containing 60 mg of calcium) was added to the diet so that the calcium content was 1.2%.
実験前の血清カルシウムは9.81±0.14mg／dlで
正常値をまし、各群間に差はなく、また低カルシ
ウム食を３日間投与した後、副甲状腺摘除を行な
うと4.60±0.28mg／dlと著明に低下した。
Serum calcium before the experiment was 9.81 ± 0.14 mg/dl, which was above the normal value, and there was no difference between the groups, and after administering a low-calcium diet for 3 days and then performing parathyroidectomy, it was 4.60 ± 0.28 mg/dl. It decreased markedly.
すなわち、低カルシウム・ビタミンＤ欠乏食と
副甲状腺摘除の効果は合せてこのような明らかな
低カルシウム血症となり、食餌中のカルシウム添
加の効果を判定する出発点として用いられる。次
に、それぞれのカルシウム添加食を６日間投与し
た後再び採血して血清カルシウムを測定した結果
を示す。 Thus, the combined effects of a low-calcium, vitamin D-deficient diet and parathyroidectomy result in such pronounced hypocalcemia, which is used as a starting point for determining the effects of dietary calcium addition. Next, after administering each calcium-added diet for 6 days, blood was collected again and serum calcium was measured. The results are shown below.
実験群 血清カルシウム値（mg／dl）
１ 4.18±0.41
２ 11.0±1.21
３ 8.56±0.37
４ 7.95±0.21
この実験結果から本発明によるカルシウム剤Ａ
は最も吸収されやすいことがわかる。副甲状腺ホ
ルモンは、血清カルシウムを正常に保つために必
要なホルモンであり、骨と血液との間のカルシウ
ムの交換を促進し、腎臓から尿の中に排泄される
カルシウムを少くし、又、腎臓での活性型ビタミ
ンＤの合成を促進して腸からのカルシウムの吸収
を盛んにすることによつて、血清カルシウムが低
くならないように働く。このために副甲状腺を外
科的に摘除すると血清カルシウムが下がる。 Experimental group serum calcium value (mg/dl) 1 4.18±0.41 2 11.0±1.21 3 8.56±0.37 4 7.95±0.21 From this experimental result, calcium agent A according to the present invention
is found to be the most easily absorbed. Parathyroid hormone is a hormone necessary to maintain normal serum calcium. It promotes the exchange of calcium between the bones and blood, reduces the amount of calcium excreted from the kidneys in the urine, and It works to prevent serum calcium from becoming low by promoting the synthesis of active vitamin D in the body and increasing the absorption of calcium from the intestines. For this reason, surgical removal of the parathyroid glands lowers serum calcium.
このようにして血清カルシウムの下がつたラツ
トでは骨と血液との間でカルシウムの交換がわる
く、腎臓からは尿の中に大量のカルシウムが失わ
れており、又腸管からのカルシウムの吸収は活性
型ビタミンＤの欠乏のために低下している。しか
しながら食餌の中に大量のカルシウムを混入する
とこのような障害を越えて血清カルシウムが種々
の程度に上昇することが知られており、食餌中の
カルシウムが体内に入る唯一つの門は腸管なの
で、もし同じ量のカルシウムが与えられたとき血
清カルシウムのよい方をみれば腸管からカルシウ
ムが吸収されて、利用される程度を正確に知るこ
とができる。この意味で副甲状腺摘除ラツトは腸
管からのカルシウムの吸収をみるのにきわめて便
利なモデルである。 In rats with low serum calcium, the exchange of calcium between bones and blood is poor, large amounts of calcium are lost from the kidneys in the urine, and absorption of calcium from the intestines is slow. Decreased due to vitamin D deficiency. However, it is known that when large amounts of calcium are mixed into the diet, serum calcium rises to various degrees beyond this disturbance, and since the only gateway for calcium in the diet to enter the body is the intestinal tract, When given the same amount of calcium, we can accurately determine the extent to which calcium is absorbed and utilized from the intestines by looking at the serum calcium value. In this sense, the parathyroidectomized rat is an extremely convenient model for examining calcium absorption from the intestinal tract.
本実験で本発明のカルシウムＡは腸管からよく
吸収され、ワダカルシウムよりも明らかによりよ
く、又通常カルシウム療法に用いられている乳酸
カルシウムと比べても吸収の良好な傾向が認めら
れ、カルシウム剤としては極めて有用であること
がわかる。 In this experiment, the calcium A of the present invention was well absorbed from the intestinal tract, clearly better than Wada calcium, and also had a tendency to be absorbed better than calcium lactate, which is commonly used for calcium therapy, and was used as a calcium agent. proves to be extremely useful.
Claims (1)
の高温で焼成することによつて得た粉末状焼成体
からなるカルシウム剤。1. A calcium agent consisting of a powdered fired product obtained by firing oyster shells at a high temperature of 1,600°C or higher while blocking oxygen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7336778A JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7336778A JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55332A JPS55332A (en) | 1980-01-05 |
| JPS6225125B2 true JPS6225125B2 (en) | 1987-06-01 |
Family
ID=13516128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7336778A Granted JPS55332A (en) | 1978-06-17 | 1978-06-17 | Calcium agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55332A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01117833A (en) * | 1987-10-29 | 1989-05-10 | Masatoshi Kato | Biologically active substance |
| JP2001240416A (en) * | 2000-02-28 | 2001-09-04 | Shozo Hori | Seashell powder for multi purpose application and its manufacturing method |
| JP2001278793A (en) * | 2000-03-29 | 2001-10-10 | Choya:Kk | Method for producing easily absorbable calcium agent |
| KR100380011B1 (en) * | 2000-09-30 | 2003-04-11 | 허일엽 | Method for Manufacturing Alkaline Mineral Drinks Utilizing of Bones of Animal or marine products and Shell |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4885721A (en) * | 1972-02-16 | 1973-11-13 |
-
1978
- 1978-06-17 JP JP7336778A patent/JPS55332A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4885721A (en) * | 1972-02-16 | 1973-11-13 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55332A (en) | 1980-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU702073B2 (en) | Pharmaceutical composition containing selected lanthanum carbonate hydrates | |
| Mai et al. | Calcium acetate, an effective phosphorus binder in patients with renal failure | |
| US5075499A (en) | Calcium supplementation by dicalcium citrate-lactate | |
| JP4929426B2 (en) | Mixed or sulfate metal salt compounds as phosphate binders | |
| RU2093160C1 (en) | Pharmaceutical composition and a method of effect on reticuloendothelium system, treatment of mucoviscidosis and chronic pain syndrome accompanying locomotor system and oncologic sicknesses | |
| JP5049589B2 (en) | Controlled release compositions containing strontium salts | |
| KR840000229A (en) | Method for preparing oral dosage form of dipyridamole | |
| Dock et al. | Cation exchangers: their use and hazards as aids in managing edema | |
| US5006551A (en) | Composition for destroying malignant tumors | |
| Morris et al. | The distribution of radioactivity following the feeding of carbon 14-labeled 2-acetylaminofluorene to rats | |
| JPS6225125B2 (en) | ||
| US4968510A (en) | Method of treating arthritis | |
| Meneely et al. | Intestinal maturation: in vivo magnesium transport | |
| US6887897B2 (en) | Calcium glutarate supplement and phosphorus binder | |
| US4098883A (en) | Aluminum compound and pharmaceutical compositions containing same | |
| JPS5711919A (en) | Manufacture of antacid substance | |
| Schaefer et al. | Calcium salts of ketoacids as a new treatment strategy for uremic hyperphosphatemia. | |
| US4840795A (en) | Preparation and method for effecting fat and lipid adsorption | |
| JPS643848B2 (en) | ||
| Mraz | Intestinal absorption of Ca-45 and Sr-85 as affected by the alkaline earths and pH. | |
| JP3348849B2 (en) | Pharmaceutical composition of gallium complex of 3-hydroxy-4-pyrone | |
| Anelli et al. | Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis: effects on acidosis, on parathyroid function, and on calcemia | |
| JPS5938206B2 (en) | Bronchial asthma treatment whose main ingredient is coenzyme Q | |
| KR870002160B1 (en) | Process for preparing modified clays | |
| US5069912A (en) | Method of treating spastic colitis |